COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population. (KBPDCN)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03974971
Recruitment Status : Active, not recruiting
First Posted : June 5, 2019
Last Update Posted : August 7, 2019
Information provided by (Responsible Party):
Kim, Seok Jin, Samsung Medical Center

Brief Summary:
Retrospective study , To analyze the clinical features and treatment outcomes in Korean blastic plasmacytoid dendritic cell neoplasm.

Condition or disease
Blastic Plasmacytoid Dendritic Cell Neoplasm

Detailed Description:

Blastic plasmacytoid dendritic cell neoplasm (BPDCN), with a synonym of blastic NK-cell lymphoma, agranular CD4+ natural killer cell leukaemia, blastic natural killer leukaemia/lymphoma, and agranular CD4+CD56+ haematodermic neoplasm/tumour, has been classified under "acute myeloid leukemia (AML) and related precursor neoplasms" since 2008 according to the World Health Organization (WHO) classification and among "myeloid neoplasm and acute leukemia" following 2016 revision of WHO classification. The plasmacytoid dendritic cells originates professional type I interferon-producing cells or plasmacytoid monocytes. Therefore, the prerequisite for diagnosis of BPDCN is the CD4+ and CD 56+ co-expression without common lymphoid or myeloid lineage markers1,2. This rare type of malignancy affecting predominantly elderly man, is reported to comprise 0.44% of hematologic malignancy3 and 0.7% of cutaneous lymphomas4, and the leukemic presentation or transformation is observed at initial presentation or even in the course of disease progression5.

Skin in¬volvement is a predominant clinical feature of BPDCN ranging in appearance from small bruise-like areas to patches, nodules, and ulcerated masses, but lymphadenopathy, splenomegaly, hepatomegaly are also commonly observed. There is no definite treatment guideline for BPDCN. Retrospective studies including acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL)/lymphoma-like chemotherapy for management of BPDCN reported 53-89% of high complete remission rates but an eventual very poor overall survival of 12-23 months, with a preponderance of ALL/lymphoma- over AML-like treatment5. Recently, targeted therapy with SL401, an IL-3 fusion protein which binds to CD123, is promising and the results of the clinical trial will be unveiled in the near future6.

Although several retrospective and small case series has been published so far7,8, there is still no multicenter study on BPDCN classified after 2008 WHO classification in Asian population. This study aims to retrospectively collect data of BPDCN patients from centers participating the Consortium for improving survival of lymphoma (CISL) and analyze the clinical features and treatment outcomes in this rare type of hematologic malignancy.

Layout table for study information
Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Other
Time Perspective: Retrospective
Official Title: Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population: A Multicenter Study
Actual Study Start Date : April 30, 2019
Actual Primary Completion Date : June 30, 2019
Estimated Study Completion Date : February 29, 2020

BPDCN diagnosis group
By review medical records Enroll patients diagnosed with BPDCN from January 1, 2000 to October 31, 2018

Primary Outcome Measures :
  1. Overall Survival Rate [ Time Frame: from the date of the IRB approval until June 30, 2019 ]
    From the date of diagnosis to the date of death, or from the date of diagnosis to the last follow-up date.

Secondary Outcome Measures :
  1. Therapeutic Response Rate [ Time Frame: from the date of the IRB approval until June 30, 2019 ]
    Therapeutic response analysis is based on the evaluation of the response of common leukemia and lymphoma

  2. Disease-free Survival Rate [ Time Frame: from the date of the IRB approval until June 30, 2019 ]
    the time from the treatment start date until the patient recurs.

  3. Number of Factors affecting overall survival [ Time Frame: from the date of the IRB approval until June 30, 2019 ]
    multivariate analysis of age, ECOG, Involving organs, Response to treatment, Treatment, Autologous transplantation/Allogeneic transplantation affecting overall survival

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
This study is a retrospective study, in which patients with patients diagnosed with SCC tumors can participate, and patients who meet the selection criteria will be eligible. The purpose of this study is explorative and descriptive, and it is impossible to calculate the statistical background. Therefore, it is estimated that more than 40 patients are diagnosed with the disease in Korea so far.

<Inclusion Criteria>

  1. Patients ≥ 18 years
  2. Pathologically confirmed diagnosis by tissue or bone marrow at each center with

    • Blastic plasmacytoid dendritic cell neoplasm
    • Blastic NK-cell lymphoma
    • Agranular CD4+ natural killer cell leukaemia
    • Blastic natural killer leukaemia/lymphoma
    • Agranular CD4+CD56+ haematodermic neoplasm/tumour
  3. Antigen expression of CD4 and/or CD56 coupled with at least one plasmacytoid dendritic cell-associated antigen among CD123, TCL1, CD2AP and BDCA2/CD303

<Exclusion Criteria>

  1. Acute myeloid leukemia
  2. Acute lymphoblastic leukemia
  3. Mixed phenotype acute leukemia
  4. Any type of B- or T-/NK/T-cell lymphomas
  5. Expression of lineage-specific markers for B cells (CD20, CD79a) T cells (CD3) Myeloid cells (myeloperoxidase) Monocytes (CD11c, CD163, lysozyme). CD34

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03974971

Layout table for location information
Korea, Republic of
Samsung medical center
Seoul, Gang Nam, Korea, Republic of, 676
Sponsors and Collaborators
Samsung Medical Center
Layout table for investigator information
Principal Investigator: Seokjin Kim, M.D., PhD Samsung Medical Center
Layout table for additonal information
Responsible Party: Kim, Seok Jin, Principal Investigator, Samsung Medical Center Identifier: NCT03974971    
Other Study ID Numbers: 2019-02-035
First Posted: June 5, 2019    Key Record Dates
Last Update Posted: August 7, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms